<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510350</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_8880_CISCO</org_study_id>
    <nct_id>NCT04510350</nct_id>
  </id_info>
  <brief_title>Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)</brief_title>
  <acronym>CISCO</acronym>
  <official_title>Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of CISCO is therefore to identify prognostic biomarkers of MS activity in&#xD;
      early-stage patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">April 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of immune subpopulations</measure>
    <time_frame>1 year</time_frame>
    <description>Correlations between the frequency of immune subpopulations, genetic profile and disease activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of immune subpopulations correlated to EDSS score</measure>
    <time_frame>1 year</time_frame>
    <description>Correlations between the frequency of immune subpopulations, genetic profile, and EDSS score ((Expanded Disability Status Scale, method of quantifying disability in multiple sclerosis, steps 1.0 to 4.5 refer to people with MS who are fully ambulatory. EDSS steps 5.0 to 9.5 are defined by the impairment to ambulation.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of immune subpopulations correlated to disease progression delay</measure>
    <time_frame>1 year</time_frame>
    <description>Correlations between the frequency of immune subpopulations, genetic profile, and delay before disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of immune subpopulations correlated to disease progression events</measure>
    <time_frame>1 year</time_frame>
    <description>Correlations between the frequency of immune subpopulations, genetic profile, and number of disease progression events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of immune subpopulations correlated to spinal lesions</measure>
    <time_frame>1 year</time_frame>
    <description>Correlations between the frequency of immune subpopulations, genetic profile, and number of new spinal lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of CIS+ patients</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of genetic and immunological profiles of CIS+ patients with healthy volunteers</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MS CIS+</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarkers analysis</intervention_name>
    <description>Genetic analysis of regions of interest</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>MS CIS+</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        After selection of the patients and volunteers of interest (number and type of clinical and&#xD;
        biological data available, heterogeneity of the chosen group...), the medical and imaging&#xD;
        data of the patients will be transmitted by OFSEP from the EDMUS database and for healthy&#xD;
        volunteers, the data of interest will be retrieved from the ABCD-SEP database&#xD;
&#xD;
        Patients CIS+ :60 Healthy Volunters : 30&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically isolated syndrome (CIS) participating in the OFSEP cohort&#xD;
             (French MS Observatory)&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Diagnosed with MS according to criteria 2017 at the time of their last visit.&#xD;
&#xD;
          -  Non-opposition to participation in the study&#xD;
&#xD;
          -  Having had at least one visit in the year following collection&#xD;
&#xD;
          -  Follow-up for at least 1 year after collection.&#xD;
&#xD;
          -  Having signed the OFSEP consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CIS patients with progressive MS&#xD;
&#xD;
        Healthy volunteers :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Having participated in the ABCD-SEP clinical trial promoted by the Rennes University&#xD;
             Hospital (NCT03744351).&#xD;
&#xD;
          -  Matched on age and sex to patients of interest in the OFSEP cohort&#xD;
&#xD;
          -  Not having objected to participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons of full age subject to legal protection (safeguard of justice, curatorship,&#xD;
             guardianship), persons deprived of liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laure Michel, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laure Michel, Md</last_name>
    <phone>2.99.28.43.21</phone>
    <phone_ext>33</phone_ext>
    <email>laure.michel@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Laure Gervais, PhD</last_name>
    <phone>2.99.28.25.55</phone>
    <phone_ext>33</phone_ext>
    <email>marie-laure.gervais@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Michel, Md</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

